Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | levcycloserine | 449215 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | levcycloserine | 449215 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | levcycloserine | 449215 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | levcycloserine | 449215 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | levcycloserine | 449215 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | myricetin | 5281672 | drug-path |
T cell receptor signaling pathway | R-HSA-983705 | map04660 | myricetin | 5281672 | drug-path |
Adipocytokine signaling pathway | R-HSA-168638 | map04920 | myricetin | 5281672 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | nilutamide | 4493 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | nilutamide | 4493 | drug-path |
Asthma | R-HSA-444620 | map05310 | nilutamide | 4493 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | nilutamide | 4493 | drug-path |
Colorectal cancer | R-HSA-4791275 | map05210 | nilutamide | 4493 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | nilutamide | 4493 | drug-path |
Ubiquitin mediated proteolysis | R-HSA-983153 | map04120 | nilutamide | 4493 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | nilutamide | 4493 | drug-path |
Cell cycle | R-HSA-1640170 | map04110 | nilutamide | 4493 | drug-path |
p53 signaling pathway | R-HSA-168638 | map04115 | nilutamide | 4493 | drug-path |
Mismatch repair | R-HSA-5358508 | map03430 | nilutamide | 4493 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | nilutamide | 4493 | drug-path |